Skip to main content
  • Home
  • Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme

Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme

Topic:
  • Heart Failure

Available Credit:

  • 1.00 MMA

Course Published On:

Course Expiry Date:

Overview

This on-demand programme, Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme, has been developed to further education among practicing cardiologists to ensure understanding of the latest developments in reverse cardiac remodelling in heart failure, how emerging data relates to current practice in Malaysia, and is intended to support the application of current understanding of treatment strategies for heart failure, and the role of cardiac remodelling, biomarkers, and provide a review of trials and latest data..

 

The programme brings together a leading international faculty from Malaysian, US, UK, and Italy, for a seven-part series.

Endorsement

This programme is endorsed by the National Heart Association to promote quality cardiovascular care through education.

Support

This programme is supported by an unrestricted educational grant from Novartis. Novartis had no involvement in the organisation of the programme.

Disclosure

In compliance with Malaysian Medical Association (MMA) guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CPD activities.

 

This programme is supported by an unrestricted educational grant from Novartis. The scientific programme has not been influenced in any way by the sponsor.

Faculty Disclosures

Dato’ Dr David Chew 

  • No conflicts of interest to declare pertaining to this programme.

 

Dr James Januzzi 

  • Grant support from Novartis Pharmaceuticals, Applied Therapeutics, and Innolife
  • Consulting income from Abbott Diagnostics, Janssen, Novartis, Quidel and Roche Diagnostics
  • Clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, CVRx, Janssen, MyoKardia, and Takeda
  • Trustee, American College of Cardiology

 

Dr Akshay Desai

  • Received consulting fees from Abbott, Alnylam, AstraZeneca, Biofourmis, Boston Scientific, Boehringer-Ingelheim, DalCor Pharma,  Merck, Novartis, Relypsa, Regeneron and Research Grants from AstraZeneca, Alnylam, and Novartis

 

Prof Andrew Coats

  • No conflicts of interest to declare pertaining to this programme.

 

Dr Michele Senni

  • Financial interest for consultancy with: Novartis, Merck, Bayer, Vifor Pharma, Abbott, Boehringer Ingelheim, Astra-Zeneca, Bioventrix, Servier

 

Dr Pardeep Jhund

  • No conflicts of interest to declare pertaining to this programme.

Terms & Conditions

Radcliffe Education requires contributors to our CME/CPD programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

This programme ‘Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice’ is accredited by the Malaysian Medical Association (MMA)  for 1 hour of external CPD credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity.

Instructions to Participants

There is no fee for taking part in this online learning activity.

 

Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

  • Cardiologists, heart failure specialists, allied health professionals, and GPs with a specialist interest in heart failure.

Learning Objectives

  • Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
  • List the main clinical implications of cardiac remodelling.
  • Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
  • Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
  • Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
  • Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.
Register now Log in

Speaker

David Chew

Dato' Dr David Chew Soon Ping is a Consultant Cardiologist at Cardiac Vascular Sentral  Kuala Lumpur (CVSKL) in Malaysia.

View full profile

James Januzzi

Massachusetts General Hospital

Dr James L Januzzi,  is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has an in-depht experience as a teacher and leads a research programme with specific focus on cardiac biomarker testing.

View full profile

Akshay Desai

Brigham and Women’s Hospital, Boston, MA, US

Prof Akshay Desai is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital. Dr Desai’s research focuses on improving care and outcomes for HF patients, as well as strategies to reduce heart failure readmissions. 

View full profile

Andrew Coats

Monash University, Australia and University of Warwick, UK

Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.

View full profile

Michele Senni

Dr Michele Senni served from 2004 to 2013 as Head of General Medicine 2 Cardiovascular Hospital of Bergamo. From 2009 to 2010 he was Chairman of the National Association of Cardiologists and Hospital Doctors (ANMCO). Today he is Director of Cardiology 1.

View full profile

Pardeep Jhund

Dr Pardeep Jhund is a Reader in Cardiology at the University of Glasgow, UK.

View full profile

This programme accredited by the Malaysian Medical Association (MMA) for 1 external CPD credit. Once the course is completed, there are instructions on how to receive your credit.

 

AVAILABLE CREDIT

1.00 Malaysian Medical Association (MMA)

Related Courses

Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice
  • 0.75 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments
  • Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
See more
Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021
  • 0.50 AMA PRA Credit

Learning objectives

  • Identify patients likely to benefit from invasive procedures versus pharmacological treatment
  • Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
See more
Hypertrophic Cardiomyopathy in Review: Highlights 2019-2021
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarize results from ongoing trials with experimental treatments
See more
Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice
  • 1.00 MMA

Learning objectives

  • Understand the latest ARNI data in HFpEF and HFrEF
  • Understand how emerging data relates to current practice in Malaysia
  • Apply current understanding of ARNI therapy in appropriate heart failure patients
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
A Review of Emerging ARNI Data in HFrEF
  • 1.00 EBAC

Learning objectives

  • Review updated data of ARNI therapy for HFrEF present at the ESC 2019;
  • understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases);
  • interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data;
  • apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized; patients
  • Apply clinical and real-world evidence data for the treatment HFrEF with ARNI therapy.
See more
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Optimising Treatment of HF
  • 1.00 (EBAC)

Learning objectives

  • Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
  • Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
  • Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
  • Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
See more
Heart Failure & Cardiomyopathy: Highlights 2019-2021
  • 0.25 AMA PRA Category 1 Credit™

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarize results from ongoing trials with experimental treatments for HFrEF and HCM
See more